75% Success Rate! Soligenix (SNGX) Stock Skyrockets on Positive Skin Cancer Treatment Data

Soligenix, Inc. (SNGX) has a reason to celebrate, and so do investors! The biopharmaceutical company just released exciting news about their HyBryte™ treatment for early-stage cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer.

Here's the lowdown: Soligenix conducted an open-label study to see how HyBryte™ would perform when used for longer periods (up to 12 months) on CTCL patients. The results are nothing short of impressive!

Early Signs Point to Success:

• 75% Success Rate: Three out of the first four patients who completed at least 12 weeks of treatment achieved "Treatment Success," meaning their cancer symptoms improved significantly.

• Fast-Acting Relief: Two patients saw improvement within just 12 weeks!

• Safe and Tolerable: No serious side effects were reported by any patients in the study.

These early findings are a major step forward in the fight against CTCL. Currently, treatment options for this cancer are limited, leaving patients with few choices.

Shining a Light on the Future:

Dr. Ellen Kim, who led the study, is optimistic about HyBryte™'s potential. "These initial results are promising and build upon the positive outcomes from previous trials," she said. "We're excited to continue working with the FDA and Soligenix to bring this potentially life-changing treatment to patients."

Investors Take Notice:

The market reacted swiftly to this positive news. Soligenix's stock price skyrocketed a whopping 283.76% to trading at $7.59 per share ahead of closing on Tuesday! This surge reflects the excitement surrounding HyBryte™'s potential to become a valuable tool in the fight against CTCL.

Soligenix isn't stopping here. They're planning a larger confirmatory Phase 3 study later this year to solidify these early findings. Stay tuned for more updates on this promising new cancer treatment!